-
Something wrong with this record ?
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
PV. Raninga, A. Lee, D. Sinha, LF. Dong, KK. Datta, X. Lu, P. Kalita-de Croft, M. Dutt, M. Hill, N. Pouliot, H. Gowda, M. Kalimutho, J. Neuzil, KK. Khanna
Language English Country Australia
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV17-30138A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011 to 2020
ProQuest Central
from 2019-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2019-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
PubMed
32373211
DOI
10.7150/thno.42705
Knihovny.cz E-resources
- MeSH
- Apoptosis drug effects genetics MeSH
- Epithelial-Mesenchymal Transition drug effects genetics MeSH
- Proteasome Inhibitors therapeutic use MeSH
- Lactones therapeutic use MeSH
- Humans MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Oxidative Phosphorylation drug effects MeSH
- Cell Proliferation drug effects genetics MeSH
- Proteasome Endopeptidase Complex drug effects metabolism MeSH
- Antineoplastic Agents therapeutic use MeSH
- Pyrroles therapeutic use MeSH
- Triple Negative Breast Neoplasms drug therapy genetics metabolism MeSH
- Xenograft Model Antitumor Assays MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required. Methods: We evaluated anti-cancer activity of a potent proteasome inhibitor, marizomib, in vitro using breast cancer lines and in vivo using 4T1.2 murine syngeneic model, MDA-MB-231 xenografts, and patient-derived tumor xenografts. Global proteome profiling, western blots, and RT-qPCR were used to investigate the mechanism of action for marizomib. Effect of marizomib on lung and brain metastasis was evaluated using syngeneic 4T1BR4 murine TNBC model in vivo. Results: We show that marizomib inhibits multiple proteasome catalytic activities and induces a better anti-tumor response in TNBC cell lines and patient-derived xenografts alone and in combination with the standard-of-care chemotherapy. Mechanistically, we show that marizomib is a dual inhibitor of proteasome and oxidative phosphorylation (OXPHOS) in TNBCs. Marizomib reduces lung and brain metastases by reducing the number of circulating tumor cells and the expression of genes involved in the epithelial-to-mesenchymal transition. We demonstrate that marizomib-induced OXPHOS inhibition upregulates glycolysis to meet the energetic demands of TNBC cells and combined inhibition of glycolysis with marizomib leads to a synergistic anti-cancer activity. Conclusions: Our data provide a strong rationale for a clinical evaluation of marizomib in primary and metastatic TNBC patients.
Institute of Biotechnology Czech Academy of Sciences Prague West 252 50 Czech Republic
Olivia Newton John Cancer Research Institute 145 Studley Road Heidelberg Vic 3084 Australia
QIMR Berghofer Medical Research Institute 300 Herston Road Herston Brisbane QLD 4006 Australia
School of Medical Science Griffith University Southport QLD 4222 Australia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026729
- 003
- CZ-PrNML
- 005
- 20211026132650.0
- 007
- ta
- 008
- 211013s2020 at f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.7150/thno.42705 $2 doi
- 035 __
- $a (PubMed)32373211
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a at
- 100 1_
- $a Raninga, Prahlad V $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
- 245 10
- $a Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition / $c PV. Raninga, A. Lee, D. Sinha, LF. Dong, KK. Datta, X. Lu, P. Kalita-de Croft, M. Dutt, M. Hill, N. Pouliot, H. Gowda, M. Kalimutho, J. Neuzil, KK. Khanna
- 520 9_
- $a Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required. Methods: We evaluated anti-cancer activity of a potent proteasome inhibitor, marizomib, in vitro using breast cancer lines and in vivo using 4T1.2 murine syngeneic model, MDA-MB-231 xenografts, and patient-derived tumor xenografts. Global proteome profiling, western blots, and RT-qPCR were used to investigate the mechanism of action for marizomib. Effect of marizomib on lung and brain metastasis was evaluated using syngeneic 4T1BR4 murine TNBC model in vivo. Results: We show that marizomib inhibits multiple proteasome catalytic activities and induces a better anti-tumor response in TNBC cell lines and patient-derived xenografts alone and in combination with the standard-of-care chemotherapy. Mechanistically, we show that marizomib is a dual inhibitor of proteasome and oxidative phosphorylation (OXPHOS) in TNBCs. Marizomib reduces lung and brain metastases by reducing the number of circulating tumor cells and the expression of genes involved in the epithelial-to-mesenchymal transition. We demonstrate that marizomib-induced OXPHOS inhibition upregulates glycolysis to meet the energetic demands of TNBC cells and combined inhibition of glycolysis with marizomib leads to a synergistic anti-cancer activity. Conclusions: Our data provide a strong rationale for a clinical evaluation of marizomib in primary and metastatic TNBC patients.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $x genetika $7 D017209
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $x genetika $7 D049109
- 650 _2
- $a epitelo-mezenchymální tranzice $x účinky léků $x genetika $7 D058750
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a laktony $x terapeutické užití $7 D007783
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a oxidativní fosforylace $x účinky léků $7 D010085
- 650 _2
- $a proteasomový endopeptidasový komplex $x účinky léků $x metabolismus $7 D046988
- 650 _2
- $a inhibitory proteasomu $x terapeutické užití $7 D061988
- 650 _2
- $a pyrroly $x terapeutické užití $7 D011758
- 650 _2
- $a triple-negativní karcinom prsu $x farmakoterapie $x genetika $x metabolismus $7 D064726
- 650 _2
- $a xenogenní modely - testy protinádorové aktivity $7 D023041
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lee, Andy $u Radiation Biology Research Center, Institute for Radiological Research, Chang Gung Memorial Hospital/Chang Gung University, Taoyuan 333, Taiwan
- 700 1_
- $a Sinha, Debottam $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
- 700 1_
- $a Dong, Lan-Feng $u School of Medical Science, Griffith University, Southport, QLD 4222, Australia
- 700 1_
- $a Datta, Keshava K $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
- 700 1_
- $a Lu, Xue $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
- 700 1_
- $a Kalita-de Croft, Priyakshi $u UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, QLD 4029, Australia
- 700 1_
- $a Dutt, Mriga $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
- 700 1_
- $a Hill, Michelle $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
- 700 1_
- $a Pouliot, Normand $u Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg Vic 3084 Australia
- 700 1_
- $a Gowda, Harsha $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
- 700 1_
- $a Kalimutho, Murugan $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
- 700 1_
- $a Neuzil, Jiri $u School of Medical Science, Griffith University, Southport, QLD 4222, Australia $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West, 252 50 Czech Republic
- 700 1_
- $a Khanna, Kum Kum $u QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane QLD 4006, Australia
- 773 0_
- $w MED00177173 $t Theranostics $x 1838-7640 $g Roč. 10, č. 12 (2020), s. 5259-5275
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32373211 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132656 $b ABA008
- 999 __
- $a ok $b bmc $g 1715465 $s 1147236
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 10 $c 12 $d 5259-5275 $e 20200406 $i 1838-7640 $m Theranostics $n Theranostics $x MED00177173
- GRA __
- $a NV17-30138A $p MZ0
- LZP __
- $a Pubmed-20211013